MGX (Metagenomi Therapeutics) Return on Gross Profit

Official company branding of Metagenomi Therapeutics (MGX)

Metagenomi, Inc. (MGX) faces risks driven by stringent FDA oversight and patent barriers, which trigger gross margin volatility. The current value of the parameter is 28.10. The asset's stability relies on the success of clinical trials and partnerships with pharmaceutical behemoths. The company's high authority in AI-driven genome editing and its status as a scientific leader create a solid foundation for business value growth.

MGX Metagenomi Gross Profitability (02/21/2024 - 11/20/2026)

Comprehensive metric breakdowns and analytics for Metagenomi (MGX)

- stock quotes and analyst forecast:
Fundamental valuation:Metagenomi Inc.
Original product of metagenomi.co

Gross margin measures direct production efficiency by determining the portion of revenue remaining after product creation costs. Gross profit margin dynamics reflect operational resilience, which for the pre-revenue platform Metagenomi, Inc. (MGX) signifies a reliance on investment capital during the development of genome editing technologies, a period where traditional profitability metrics temporarily give way to strategic capital development.

Main competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability